Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) EBIT Margin (2021 - 2025)

Oncology Institute's EBIT Margin history spans 5 years, with the latest figure at 4.87% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 703.0% year-over-year to 4.87%; the TTM value through Dec 2025 reached 7.18%, up 810.0%, while the annual FY2025 figure was 7.18%, 810.0% up from the prior year.
  • EBIT Margin reached 4.87% in Q4 2025 per TOI's latest filing, up from 5.9% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 2.24% in Q2 2021 to a low of 78.07% in Q4 2021.
  • Average EBIT Margin over 5 years is 20.26%, with a median of 16.79% recorded in 2023.
  • The largest YoY upside for EBIT Margin was 4295bps in 2022 against a maximum downside of -2988bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 78.07% in 2021, then skyrocketed by 55bps to 35.11% in 2022, then soared by 49bps to 17.82% in 2023, then surged by 33bps to 11.9% in 2024, then surged by 59bps to 4.87% in 2025.
  • Per Business Quant, the three most recent readings for TOI's EBIT Margin are 4.87% (Q4 2025), 5.9% (Q3 2025), and 9.36% (Q2 2025).